Table 4 Characteristic of AML patients in validation cohort

Median age

43.08

43.25

0.567

Female, no. (%)

10(40)

13(52)

0.395

Secondary or treatment-related AML, no. (%)

2(8)

2(8)

>0.99

FAB subtype , no.

0.838

 M₁

3

3

 M₂

10

12

 M₄

7

5

 M₅

1

3

 M₆

2

0

 NA

2

2

Median WBC, 10⁹/L (range)

6.83(0.3–244.38)

23.88(0.68–366)

0.289

Median BM plasts, %, (range)

49.5(11–94)

65.5(22–90.5)

0.175

Median platelet count, 10⁹/L (range)

39(4–151)

35.5(4–180)

0.918

CEBPA mutated, no. (%)

2(8)

5(20)

0.179

Missing date

1

3

NPM1 mutated, no. (%)

2(8)

4(16)

0.327

Missing date

1

3

IDH1 mutated, no. (%)

0

0

>0.99

Missing date

1

3

FLT3-TKD mutated, no. (%)

0

1(4)

0.296

Missing date

1

3

FLT3-ITD mutated, no. (%)

0

2(4)

0.149

Missing date

1

3

AML1/ETO mutated, no. (%)

4(16)

6(24)

0.389

Missing date

1

3

C-KIT D816V mutated, no. (%)

1(4)

2(8)

0.504

Missing date

1

3

CBEB-MYH11 mutated, no. (%)

2(8)

3(12)

0.568

Missing date

1

3